ClinicalTrials.gg
RecruitingNCT06772766Updated Jan 14, 2025

A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia

A Phase 1 interventional study of 9MW3011 and 9MW3011 placebo in Beta-Thalassemia, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.

Planned enrollment
8th of 34
40 · median 10
Started
2024
with 10 others
Phase 1
8 of 44
4 open now
Primary completion
2026-10
later than 7 of 24 live
Registered
43rd of 44
by date

Among the 44 studies in beta-Thalassemia with a site in China, this one is the 8th largest by planned enrollment of the 34 interventional ones that give a count, is one of 11 that started in 2024, is one of 8 in phase 1, reaches primary completion later than 7 of the 24 other live ones, and was the 43rd registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in beta-Thalassemia with a site in China, or all of them as a file.
02

Study summary

This is a phase Ib, randomized, double-blind, placebo-controlled, multiple ascending dose study . The objectives of the study are to evaluate the safety , tolerability, pharmacokinetics(PK), pharmacodynamics(PD), and immunogenicity of 9MW3011 in patients with non-transfusion-dependent β- thalassemia .

Read the detailed description

A total of 40 subjects diagnosed with non-transfusion-dependent β-thalassemia will be enrolled in this study and assigned into four dosage cohorts. In each cohort, subjects will be randomized in a 4:1 ratio to receive 9MW3011 or placebo via intravenous infusion.

03

Conditions studied

  • Beta-Thalassemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male and female subjects aged 18 to 65 years (inclusive)
  2. Subject must have a documented genetic diagnosis of β-thalassemia or E/ β-thalassemia
  3. Subjects must meet the criteria for non-transfusion-dependent thalassemia
  4. Subjects must have a baseline hemoglobin level between 70-100 g/L(inclusive), based on 2 consecutive measurements taken at least 1 week apart within 4 weeks before randomization
  5. Subjects must have evidence of iron overload during screening
  6. Subject must have performance status: (ECOG) performance score of 0 to 1
  7. Subjects must fully understand the study procedures and methods, voluntarily participate in the trial, and sign an form

Key Exclusion Criteria:

  1. Subjects diagnosed with alpha-thalassemia
  2. Subjects diagnosed with HbS/beta-thalassemia or transfusion-dependent beta-thalassemia
  3. Subjects exhibit severe iron overload at the time of screening
  4. In addition to thalassemia, subjects have any other forms of anemia and hematological disorders that the investigator assesses may compromise safety or influence study outcomes
  5. Combined with any significant systemic diseases or psychiatric disorders
  6. Subjects have (NYHA) Class III-IV heart failure and other cardiovascular diseases within 6 months prior to screening or currently present
  7. During the screening or baseline period, subjects exhibiting a interval of ≥450ms for males and ≥470ms for females on a 12-lead (ECG), or presenting an abnormal 12-lead ECG with clinical significance
  8. Uncontrolled hypertension before screening
  9. A history of malignant neoplasm occurring within the last five years
  10. Severe infection requiring hospitalization or intravenous antimicrobial therapy, or uncontrolled systemic bacterial, fungal, or viral active infection
  11. Subject have received concomitant treatment that was not permitted by the protocol
  12. Subjects whose hematological parameters did not meet the inclusion criteria during screening
  13. Subjects with a history of substance abuse, as well as those who yield positive results on substance abuse screening
  14. Subjects who are unable to undergo MRI scans
  15. Pregnant or lactating women
  16. Subjects presenting any other factors deemed unsuitable for participation assessed by the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    9MW3011 or placebo (Randomized 4:1)

    Drug: 9MW3011 · Drug: 9MW3011 placebo

  • Experimental
    Cohort 2

    9MW3011 or placebo (Randomized 4:1)

    Drug: 9MW3011 · Drug: 9MW3011 placebo

  • Experimental
    Cohort 3

    9MW3011 or placebo (Randomized 4:1)

    Drug: 9MW3011 · Drug: 9MW3011 placebo

  • Experimental
    Cohort 4

    9MW3011 or placebo (Randomized 4:1)

    Drug: 9MW3011 · Drug: 9MW3011 placebo

Interventions

  • Ascending IV doses administered per protocol

  • Drug9MW3011 placebo

    Ascending IV doses administered per protocol

06

What researchers measure

Primary outcomes

  1. Adverse Event(including serious adverse event)

    The incidence of Adverse Events(AEs)and Serious Adverse Events(SAEs)from treatment until the last scheduled follow-up visit

    Time frame: up to day 169

  2. Number of subjects with abnormal vital signs

    Vital signs measurements will include pulse rate, respiration rate, blood pressure (systolic and diastolic blood pressure) and body temperature.

    Time frame: up to day 169

  3. Number of subjects with abnormal clinically significant results from physical examination

    The physical examinations will include examination of the following: skin and mucous membranes, lymph nodes, head and neck, chest, abdomen, musculoskeletal, nervous system, and other sites of note elicited from the subject.

    Time frame: up to day 169

  4. Number of subjects with abnormal clinically significant 12-lead electrocardiogram (ECG) parameters

    The examination indicators include heart rate, PR, QRS, uncorrected QT, and QTcF(corrected by Fridericia formula).

    Time frame: up to day 169

  5. Number of subjects with abnormal clinically significant clinical laboratory results

    Clinical laboratory tests include hematology, urinalysis, blood chemistry, coagulation function.

    Time frame: up to day 169

Secondary outcomes

  1. Concentration of 9MW3011 in serum

    Time frame: up to day 169

  2. PD-parameters-hepcidin

    Change from baseline in hepcidin levels

    Time frame: up to day 169

  3. PD-parameters-serum iron

    Change from baseline in serum iron levels

    Time frame: up to day 169

  4. Anti-drug antibody(ADA)

    The incidence of ADA

    Time frame: up to day 169

  5. Liver iron concentration(LIC)

    Change from baseline in LIC

    Time frame: up to day 169

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Oct 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 14, 2025
StartActual
Dec 30, 2024
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06772766
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Dec 30, 2024
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jan 14, 2025

Study contacts

Yongrong Lai
Contact
laiyongrong@hotmail.com
+8607715356304

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-TMPRSS6 Monoclonal Antibody DISC-3405

Start the discussion